

## Special Issue

# Liposomal Drug Delivery: Three Decades from the First Liposomal Drug Delivery Medicine in Clinical Use

### Message from the Guest Editors

Liposomes are the first nanomedicines approved three decades back. From then to today, liposomal drug delivery have consistently played a central role in nanomedicine. Liposomal drugs are marketed medicines with great potential in the field of cancer therapy as well as other chronic and infectious diseases. This Special Issue is concerned with the applications of liposomes in physical chemistry, biology, pharmaceutical technology, and medicine. Topics may include physicochemical studies, self-assembly behavior, interactions of lipids/liposomes with active pharmaceutical ingredients and/or other excipients, the impact of liposomes on the drug release mechanism, as well as the utilization of liposomes as models of cellular membranes. The formation, preparation, and drug loading/release of lipid-based nanocarriers, liposomes, and hybrid liposomal carriers (combination with other nanomaterials) are hot topics in the current literature. Special attention will be given to applications of liposomes in the delivery of proteins/nucleic acids, in vaccinology, and immunology of cancer. Both original manuscripts and reviews are welcome.

---

### Guest Editors

Dr. Natassa Pippa

Department of Pharmacy, National & Kapodistrian University of Athens, Athens, Greece

Dr. Asterios (Stergios) Pispas

Theoretical and Physical Chemistry Institute, National Hellenic Research Foundation, 48 Vassileos Constantinou Ave., 11635 Athens, Greece

---

### Deadline for manuscript submissions

closed (31 October 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/119702](https://mdpi.com/si/119702)

*Biomedicines*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).